Lactic acid bacteria and application thereof

Through the lactic acid bacteria Lactiplantibacillus plantarum SCZH-7 screened from the manure of red-crowned crane, the problem of insufficient antibiotic resistance and probiotic development in the intestinal diseases of red-crowned cranes was solved, and effective probiotic agents for the intestinal cranes were provided, thus achieving the effect of the intestinal cranes. Inhibition of bacteria and improvement of intestinal health.

CN118995495APending Publication Date: 2024-11-22SICHUAN AGRI UNIV

Patent Information

Application Number
CN202411109383.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There is a lack of development of beneficial bacteria in the intestine of the red-crowned crane in the prior art, especially the lactic acid bacteria from the red-crowned crane has not been fully developed, and the drug resistance of antibiotics to intestine diseases of the red-crowned crane is difficult to solve.

Method used

Lactiplantibacillus plantarum SCZH-7 was screened from the red-crowned crane feces in Emeishan, Sichuan. This strain has an inhibitory effect on Gram-positive and Gram-negative pathogenic bacteria, and was prepared into bacterial solution, fermentation broth and lyophilized powder for preparation of probiotic bacteria. agent, used in dairy products, cosmetics, fermented foods and antibiotics.

Benefits of technology

It enriches the storage library of lactic acid bacteria species, effectively inhibits the growth of E. coli, Salmonella and Staphylococcus aureus, provides anti-inflammatory and resilient effects, and is suitable for the prevention and treatment of intestinal diseases of the red-crowned crane.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995495A_ABST
    Figure CN118995495A_ABST
Patent Text Reader

Abstract

The invention discloses a lactic acid bacterium and application thereof, the lactic acid bacterium is named as Lactiplantibacillus plantarum SCZH-7 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 2024523, and the preservation date is March 18, 2024. The Lactobacillus plantarum SCZH-7 disclosed by the invention has a relatively good inhibition effect on Gram-positive and Gram-negative pathogenic bacteria, can enrich the preservation library of Lactobacillus strains, and is widely applied to dairy products, cosmetics, fermented foods and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, in particular to a lactic acid bacterium and application thereof. Background Art

[0002] Lactic acid bacteria are one of the most widely studied probiotics. Lactic acid bacteria can ferment carbohydrates to produce lactic acid, which is more suitable for processing, storage and survival through the gastrointestinal tract. Studies have shown that lactic acid bacteria can enhance the intestinal epithelial barrier, secrete antimicrobial substances (bacteriocins, organic acids, hydrogen peroxide, etc.), regulate intestinal flora, participate in immunity, etc., thereby exerting their probiotic properties. Ideal lactic acid bacteria strains should meet the following conditions: they must be non-pathogenic and non-toxic, and have beneficial effects on the host. In addition, they should be able to survive through the gastrointestinal tract and adhere to intestinal epithelial cells; produce antimicrobial substances against pathogenic bacteria; remain active during storage and use; have good sensory properties; and be separated and intended for use in the same species.

[0003] The crested ibis is known as the jewel of the East. It is a vulnerable endemic species that is very popular around the world. It is an omnivorous bird that is susceptible to various intestinal diseases due to environmental and human factors. The prevention and treatment of diseases rely on antibiotics, but antibiotics are resistant. Lactic acid bacteria are one of the best alternatives. However, as one of the beneficial flora in the intestines of crested ibis, crested ibis-derived lactic acid bacteria have not yet been developed. Although there are studies on the isolation and screening of crested ibis-derived lactic acid bacteria, they are basically limited to this. Summary of the invention

[0004] The purpose of the present invention is to provide a lactic acid bacterium and its application. The lactic acid bacterium is selected from the feces of crested ibis and has good probiotic properties. The lactic acid bacterium has a good inhibitory effect on Gram-positive and Gram-negative pathogenic bacteria, can enrich the collection of lactic acid bacteria, and is used in dairy products, cosmetics, and fermented foods.

[0005] In order to solve the problems existing in the prior art, the technical solution adopted by the present invention is:

[0006] In the first aspect, the present invention provides a lactic acid bacterium, which is named Lactiplantibacillus plantarum SCZH-7, deposited in the China Center for Type Culture Collection (CCTCC), with a deposit number of CCTCCNO: M2024523, a deposit address of Wuhan University, Wuhan, China, and a deposit date of March 18, 2024.

[0007] The lactic acid bacteria SCZH-7 is selected from fresh excrement of crested ibis in Mount Emei, Sichuan. The morphological characteristics of the lactic acid bacteria are: white or milky yellow colonies with neat edges, a raised center and a smooth surface.

[0008] Furthermore, the gene sequence of the lactic acid bacteria is shown in SEQ ID NO.1.

[0009] In a second aspect, the present invention provides use of the lactic acid bacteria described in the first aspect in preparing a probiotic.

[0010] In a third aspect, the present invention provides a probiotic comprising the lactic acid bacteria SCZH-7 described in the first aspect, or a bacterial liquid comprising lactic acid bacteria SCZH-7, or a fermented liquid comprising lactic acid bacteria SCZH-7, or a freeze-dried powder comprising lactic acid bacteria SCZH-7.

[0011] Furthermore, the viable count of the lactic acid bacteria SCZH-7 in the probiotic is 10 8 -10 9 CFU / mL.

[0012] Furthermore, the method for preparing the bacterial solution comprises the following steps:

[0013] A single colony of SCZH-7 was inoculated into MRS broth and cultured at 37°C for 23-25 ​​hours to obtain a bacterial solution.

[0014] Furthermore, the method for preparing the fermentation broth comprises the following steps:

[0015] A single colony of SCZH-7 was inoculated into MRS broth and cultured at 37°C for 23-25 ​​hours to obtain an activated bacterial solution. The activated bacterial solution was centrifuged for 8-12 minutes to remove the bacteria, and then filtered through a microporous filter membrane to obtain a fermentation liquid.

[0016] Furthermore, the preparation method of the freeze-dried powder comprises the following steps:

[0017] Take a single colony of SCZH-7 and inoculate it into MRS broth, culture it at 37°C for 23-25h to obtain an activated bacterial solution, add the activated bacterial solution into a freezing tube, add an equal volume of sterile skim milk, then plug an absorbent cotton ball on the top of the freezing tube, and freeze-dry it under vacuum to obtain a lyophilized powder.

[0018] In a fourth aspect, the present invention provides the use of the lactic acid bacteria described in the first aspect and the probiotics described in the third aspect in the preparation of dairy products, cosmetics, fermented foods, and antibiological agents for inhibiting infection by Gram-positive and Gram-negative pathogens.

[0019] In a fifth aspect, the present invention provides a dairy product, comprising the lactic acid bacteria described in the first aspect or the probiotic agent described in the third aspect.

[0020] In a sixth aspect, the present invention provides a cosmetic comprising the lactic acid bacteria described in the first aspect or the probiotic agent described in the third aspect.

[0021] Furthermore, the cosmetics may also include one or more auxiliary materials commonly used in the art, such as moisturizers, emollients, emulsifiers, colorants, fragrances, oily raw materials, surfactants, stabilizers, thickeners, binders, and preservatives.

[0022] Furthermore, the cosmetic has the effects of anti-oxidation and scavenging free radicals.

[0023] In a seventh aspect, the present invention provides a fermented food, wherein the fermented food comprises the lactic acid bacteria described in the first aspect or the probiotic agent described in the third aspect.

[0024] Furthermore, the fermented food may also include one or more additives known in the art, such as flavoring agents, colorants, fillers, disintegrants, sweeteners, lubricants, binders, and pH regulators.

[0025] In an eighth aspect, the present invention provides an antimicrobial additive for inhibiting infection by Gram-positive pathogens and Gram-negative pathogens, wherein the antimicrobial additive contains the lactic acid bacteria described in the first aspect or the probiotic agent described in the third aspect.

[0026] The advantages and beneficial effects of the present invention are:

[0027] The present invention screens out lactic acid bacteria Lactiplantibacillus plantarum from the feces of Sichuan crested ibis, which has a good inhibitory effect on both Gram-positive and Gram-negative pathogens. The lactic acid bacteria liquid, fermentation liquid and freeze-dried powder prepared by the present invention can effectively inhibit the growth of Escherichia coli, Salmonella and Staphylococcus aureus, laying a theoretical foundation for further research on intestinal probiotics of crested ibis. The present invention enriches the collection of lactic acid bacteria strains and can be used in dairy products, cosmetics and fermented foods. The present invention can inhibit the inflammatory response caused by common pathogens and can be used to prepare cosmetics with anti-inflammatory and soothing effects. The present invention has a fermentation function, can produce lactic acid, and can be used in dairy products and fermented foods. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 It is the colony morphology of lactic acid bacteria;

[0029] Figure 2 This is the result of Gram staining of lactic acid bacteria;

[0030] Figure 3 Construction of branching tree results for lactic acid bacteria;

[0031] Figure 4 Lactic acid bacteria growth curve determination;

[0032] Figure 5 is the hemolytic activity result, where:

[0033] Figure 5 A is the result of hemolytic activity of ETEC CVCC196; Figure 5 B is the hemolytic activity result of Lactiplantibacillus plantarumSCZH-7. DETAILED DESCRIPTION

[0034] The following will be combined with the drawings in the embodiments of the present application to clearly describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, rather than all the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments in the present application belong to the scope of protection of this application.

[0035] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0036] Columbia blood agar plates were purchased from a biological company in Qingdao. The components of various culture media are as follows:

[0037] The composition of MRS broth is shown in Table 1:

[0038] Table 1

[0039]

[0040]

[0041] The composition of MRS agar is shown in Table 2:

[0042] Table 2

[0043]

[0044] The composition of LB broth is shown in Table 3:

[0045] Table 3

[0046]

[0047] The composition of nutrient agar (NA) is shown in Table 4:

[0048] Table 4

[0049]

[0050] Example 1

[0051] 1. Isolation and screening of strains

[0052] Fresh feces of adult crested ibis were collected from the crested ibis breeding base in Mount Emei, Sichuan. Weigh 1 g of fresh crested ibis feces and add it to a 50 ml centrifuge tube (with glass beads) containing 9 ml of sterile saline and shake for 20 min. The above mixing concentration is 10 -1 According to the dilution method, 10 -1 Mix the solution and dilute to 10 -3 Take 100 μL of 10 -3 The mixture was evenly coated on MRS agar and placed in a 37°C constant temperature incubator for anaerobic culture for 24 hours. A single colony of suspected lactic acid bacteria was picked up by an inoculation loop and repeatedly streaked on MRS agar for purification until no foreign bacteria were found under microscopic examination. The colony morphology of the isolated strain on MRS agar was observed with the naked eye, and the bacterial morphology was observed under Gram staining microscopy.

[0053] Results: One target lactic acid bacteria strain was screened out, such as Figure 1 As shown in the figure, the suspected colonies on MRS agar appear as white or creamy yellow colonies with neat edges, a raised center, and a smooth surface. Figure 2 As shown, Gram staining microscopy showed positive rod-shaped bacteria.

[0054] 2.16S rRNA molecular biological identification

[0055] The strain obtained by screening was cultured at 37°C overnight to obtain bacterial liquid, centrifuged at 4000×g for 10 min to collect bacterial precipitate, washed 2-3 times with sterile saline, and the bacterial genomic DNA was extracted using the bacterial genomic DNA rapid extraction kit of Sangon Biotech (Shanghai) Co., Ltd. The genomic DNA of the strain was used as a template and 16SrDNA PCR amplification was performed using universal primers 27F and 1492R. The 25μL amplification system was: 12.5μL 2xTaq MasterMix, 1.5μL each of the upstream and downstream primers (27F: 5'-GAGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO.2), 1492R: 5'-AAGGAGGT-GATCCAGCCGCA-3' (SEQID NO.3)), 2μL template DNA, and 7.5μL ddH2O. The amplification program was: 94°C for 4 min, (94°C for 30 s, 58°C for 30 s, 72°C for 2 min) for 30 cycles, and 72°C for 10 min. The concentration and fragment size of the PCR product were detected by 1.0% agarose gel electrophoresis, and the product was sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing. The sequencing results were analyzed by BLASTn sequence alignment analysis using the GenBank database, and the genetic distance between different species was analyzed using MEGA 6.0 software, and the phylogenetic tree was constructed using Neighbor-Joining.

[0056] Results: The selected lactic acid bacteria strain with high inhibitory activity was identified and sequenced, and it was Lactobacillus plantarum. Its gene sequence is shown in SEQ ID NO.1. The strain was named Lactiplanibacillus plantarum SCZH-7, and its sequence was uploaded to the China Center for Type Culture Collection and obtained the number CCTCC NO:M 2024523. Construction of branch tree results Figure 3 As shown:

[0057] 3. Physiological and biochemical identification

[0058] Lactiplantibacillus plantarum SCZH-7 was identified physiologically and biochemically with reference to the Bergey's Manual of Bacterial Identification and Lactic Acid Bacteria Isolation, Identification and Experimental Methods.

[0059] Results: The bacteria showed positive reactions in the biochemical identification reactions of sucrose, xylose, salicin, glucose, lactose, inulin, raffinose, cellobiose, esculin, maltose, sorbitol and mannitol.

[0060] Table 5 Physiological and biochemical identification results of isolated strains

[0061]

[0062]

[0063] 1 +, positive or weakly positive reaction; -, negative reaction.

[0064] 4. Growth Curve Determination

[0065] Inoculate a single colony of Lactiplantibacillus plantarum SCZH-7 in 200 mL of MRS broth, cover the surface with sterile liquid paraffin to form an anaerobic environment, and culture at 37 °C in a shaking incubator for 24 h. Take samples every 2 h to measure the OD value of the bacterial solution. 600 There were 10 times in total, with the culture time as the horizontal axis and the OD600 value as the vertical axis to record the results and draw a growth curve.

[0066] The results are as follows Figure 4 When the culture temperature was 37℃, Lactiplantibacillus plantarum SCZH-7 entered the logarithmic growth phase after 8 hours and entered the flat growth phase after 15 hours.

[0067] 5. Determination of acid and bile resistance

[0068] Collect the 24h culture of Lactiplantibacillus plantarum SCZH-7 and adjust the bacterial concentration to 10 8 CFU / mL, inoculated into MRS broth adjusted to pH=1.0, pH=2.0 and pH=3.0 with 5mol / L hydrochloric acid at a 1% (v / v) addition, cultured at 37°C, sampled at 0h and 3h, and the number of viable bacteria was determined by MRS agar plate counting method. The same operation was performed, and the bacteria were transferred to MRS broth with a volume concentration of 0.3%, 1.0%, and 2.0% pig bile salt at a 1% (v / v) addition, cultured at 37°C, sampled at 0h and 4h, and the number of viable bacteria was determined by MRS agar plate counting method.

[0069] Results: Under the conditions of pH=3.0 and pig bile salt concentration of 0.3%, the survival number of Lactiplantibacillus plantarumSCZH-7 could be greater than 10 6 CFU / mL. Under the conditions of pH=2.0 and pig bile salt concentration of 1% and 2%, the survival number of Lactiplantibacillus plantarum SCZH-7 can be greater than 10 5 CFU / mL. In the strong acid condition of pH=1.0, the survival number of Lactiplantibacillus plantarum SCZH-7 was still greater than 10 3 CFU / mL, the results showed that Lactiplantibacillus plantarumSCZH-7 has good acid and bile resistance.

[0070] Table 6 Acid resistance of lactic acid bacteria under different acidic conditions (logCFU / mL)

[0071]

[0072] Table 7 Survival rate of lactic acid bacteria under different concentrations of bile salt (logCFU / mL)

[0073]

[0074] 6. In vitro antibacterial performance test

[0075] The punch method was used to detect the antibacterial effect of Lactiplantibacillus plantarum SCZH-7 on Escherichia coli, Salmonella and Staphylococcus aureus.

[0076] Take a single colony of Lactiplantibacillus plantarum SCZH-7 and inoculate 1 mL of MRS broth. Culture at 37°C for 24 h to obtain 10 9 CFU / mL of activated bacterial liquid. Take the activated bacterial liquid, centrifuge at 15,600×g for 10 minutes, remove the bacteria, and then filter through a 0.22um microporous filter membrane to obtain the fermentation liquid. Inoculate single colonies of Escherichia coli, Salmonella, and Staphylococcus aureus into 3mL LB broth, culture at 37℃ for 18h, and dilute to 10 6 CFU / mL is used as indicator bacteria. Take 100μL indicator bacteria solution and evenly spread it on nutrient agar (NA). After it is absorbed, use a sterile puncher with a diameter of 8mm to punch holes, draw 200μL of strain fermentation liquid into the hole, and measure the diameter of the inhibition zone after culturing at 37℃ for 12h.

[0077] Results: Lactiplantibacillus plantarum SCZH-7 had good antibacterial activity against Escherichia coli, Salmonella and Staphylococcus aureus. The diameters of the inhibition zones were all >16 mm (Table 8).

[0078] Table 8 Diameter of common pathogens inhibited by LAB (mm)

[0079]

[0080]

[0081] 7. Antimicrobial susceptibility

[0082] The drug sensitivity test of Lactiplantibacillus plantarum SCZH-7 was carried out by drug paper agar diffusion method. 8 CFU / m) and different types of drug sensitivity tablets (purchased from Hangzhou Microbiological Reagent Co., Ltd.) were placed on the surface of MRS agar plates. The inhibition zone was measured and recorded after 12 hours of inoculation at 37°C, and the results were compared with the interpretation zone diameter described in the performance standard of antimicrobial drug paper sensitivity test. The antibiotics tested included penicillin, cefoperazone, cephradine, carbenicillin, chloramphenicol, tetracycline, doxycycline, erythromycin, ciprofloxacin, gentamicin, kanamycin, and vancomycin. The test results were used to determine drug sensitivity in accordance with the latest CLSI (2009) standards.

[0083] Results: Lactiplantibacillus plantarum SCZH-7 was resistant to cefradine, ciprofloxacin and vancomycin, and was sensitive to 9 antibiotics (Table 9).

[0084] Table 9. Susceptibility of LAB to antimicrobial drugs

[0085]

[0086] Note: PNC penicillin, CFP cefoperazone, CE cefoperazone, CB carbenicillin, CHL chloramphenicol, TE tetracycline, DC doxycycline, ERY erythromycin, CIP ciprofloxacin, GM gentamicin, KAN kanamycin, VAN vancomycin

[0087] 1 R—resistant; M—moderately sensitive; S—sensitive

[0088] 8. Hemolytic activity

[0089] Use an inoculation loop to dip the activated bacterial solution of Lactobacillus plantarum SCZH-7 (10 8 CFU / mL) were streaked onto Columbia blood agar plates containing 5% by volume sheep blood and incubated at 37°C for 24 h. ETEC CVCC 196 (purchased from the China Veterinary Drug Administration) was used as a positive control. The isolates were then checked for clear areas around the colonies.

[0090] Results: On blood agar plates, ETEC CVCC196 was γ-hemolyzed ( Figure 5 A). However, Lactiplantibacillus plantarum SCZH-7 showed no hemolytic activity ( Figure 5 B).

[0091] 9. Whole genome sequencing analysis

[0092] The whole genome sequencing sequence of Lactobacillus plantarum SCZH-7 was uploaded to NCBI to obtain the accession number (CP158575.1). Functional annotation was completed in the Kyoto encyclopedia of Gene and Genomes (KEGG) database by blast search. AntiSMASH was used to search for secondary metabolites. The virulence factor database of pathogenic bacteria (VFDB) was used to retrieve pathogenic genes.

[0093] Results: Many genes that were potential probiotic markers were identified in the Lactiplantibacillus plantarum SCZH-7 genome, such as acid resistance (atpA, atpB, atpC, atpD, etc.), bile resistance (bsh), temperature resistance (gorEL, csp, danJ, dnaK), oxidative stress (arsC, trxA, trxB, nfrA1) and cell adhesion (luxS, scpA, scpB).

[0094] In addition, the Lactiplantibacillus plantarum SCZH-7 genome carries a bacteriocin biosynthesis genomic cluster (RiPP-like and T3PK3).

[0095] Only a few virulence genes related to adhesion, stress survival, exoenzymes, immune regulation, and regulatory factors were detected in the genome data of Lactiplantibacillus plantarum SCZH-7. These virulence genes were not related to pathogenicity.

[0096] Example 2

[0097] This embodiment provides a method for preparing a lactic acid bacteria SCZH-7 bacterial liquid, comprising the following steps:

[0098] Take a single colony of lactic acid bacteria SCZH-7 and inoculate it into 200 ml of MRS broth. Cover the surface with sterile liquid paraffin to form an anaerobic environment. Place it in a shaker and culture it at 37°C for 24 hours to obtain a bacterial solution. Adjust the concentration of the bacterial solution to 10 9 CFU / mL.

[0099] Example 3

[0100] This embodiment provides a method for preparing a lactic acid bacteria SCZH-7 fermentation broth, comprising the following steps:

[0101] Take a single colony of Lactiplantibacillus plantarum SCZH-7 and inoculate 1 mL of MRS broth. Culture at 37°C for 24 h to obtain an activated bacterial solution. Take the activated bacterial solution, centrifuge it at 15,600 × g for 10 min, remove the bacteria, and then filter it through a 0.22 μm microporous membrane to obtain a fermentation solution. Adjust the concentration of the fermentation solution to 10 9 CFU / mL.

[0102] Example 4

[0103] This embodiment provides a method for preparing a freeze-dried powder of lactic acid bacteria SCZH-7, comprising the following steps:

[0104] Take a single colony of Lactiplantibacillus plantarum SCZH-7 and inoculate it into MRS broth, and culture it at 37℃ for 24h. Get the activated bacterial solution. Take 0.9ml of the activated bacterial solution and add it to a cryopreservation tube, add an equal volume of sterile skim milk, and then plug the top of the cryopreservation tube with a cotton ball. After freeze-drying under vacuum, a lyophilized powder is obtained and stored in a -80℃ refrigerator.

[0105] Example 5

[0106] This embodiment provides a probiotic agent, which contains the lactic acid bacteria SCZH-7 bacterial liquid described in Example 2.

[0107] Example 6

[0108] This embodiment provides a probiotic agent, which contains the fermentation liquid of the lactic acid bacteria SCZH-7 described in Example 3.

[0109] Example 7

[0110] This embodiment provides a probiotic agent, which contains the freeze-dried powder of lactic acid bacteria SCZH-7 described in Example 4.

[0111] Application Example 1

[0112] The lactic acid bacteria SCZH-7 bacterial liquid described in Example 2 was used for animal experiments.

[0113] 45 SPF male Kunming mice (7 weeks old), weighing 18–22 g, were provided by Chengdu Dashuo Biotechnology Co., Ltd. The animal study was approved by the Institutional Animal Care and Use Committee of Sichuan Agricultural University (approval number: DY2021203027).

[0114] The mice were placed under well-ventilated and light conditions (temperature 22 ± 1.5 °C; free access to water). Adaptive feeding was performed for 5 days. Subsequently, 45 mice were randomly divided into 3 groups (15 mice in each group): (1) control group, each mouse was gavaged with 200 μL sterile saline for 21 days; (2) model group, each mouse was gavaged with 200 uL sterile saline for 14 days, and was deprived of food and water for 4 hours from day 15 to 19, and gavaged with 200 uL Salmonella (5 × 10 8 CFU / mL); 200uL sterile saline was gavaged on days 20-21. (3) Probiotic group: 200uL SCZH-7 bacterial solution prepared in Example 2 was gavaged on days 1-14. Food and water were withheld for 4 hours on days 15-19. Each mouse was given 200uL SCZH-7 (2×10 10 CFU / mL) by gavage, and in the afternoon, 200uL of Salmonella typhimurium (5×10 8 Each mouse was challenged with 200uL SCZH-7 (2×1010 CFU / mL) on day 20-21. The body weight of mice was monitored throughout the experiment, and mice were euthanized after the experiment.

[0115] The spleen and liver were harvested from each group of mice. The weight of the whole spleen and liver was weighed immediately and calculated according to the following formula: The organ index was expressed as the ratio of organ weight to body weight (mg / g).

[0116] For each mouse, eyeball blood was collected. Serum was collected for cytokine measurement at 4 °C for 4 hours. Cytokines in serum, including mouse TNF-α, IL-1β, and IL-6, were quantified using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's protocol (R&D Systems, MN, United States). The readings were measured at a wavelength of 450 nm using a Synergy HTTR microplate reader.

[0117] result:

[0118] During the whole experimental period, the body weights of mice in the three groups increased (Table 10), but there were no significant differences among the groups.

[0119] Table 10 Growth performance parameters of mice in each group

[0120]

[0121] During the entire experimental period, the changes in organ indexes of mice in the three groups were statistically analyzed (Table 11), but there was no significant difference among different groups.

[0122] Table 11 Changes in organ index

[0123]

[0124] Compared with the control group, the inflammatory cytokines IL-1β and IL-6 in the model group mice increased significantly after being challenged with Salmonella (P < 0.05) (Table 12), indicating that the model group mice had an inflammatory response. However, in the mice challenged with probiotics and Salmonella at the same time, these two cytokines decreased significantly, indicating that the use of SCZH-7 can improve the inflammatory response of mice.

[0125] Table 12 Changes of serum inflammatory cytokines

[0126]

[0127] The embodiments of the present application are described above in conjunction with the accompanying drawings, but the present application is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the guidance of the present application, ordinary technicians in this field can also make many forms without departing from the purpose of the present application and the scope of protection of the claims, all of which are within the protection of the present application.

Claims

1. A lactic acid bacterium, characterized in that: The lactic acid bacteria are named Lactiplantibacillus plantarum SCZH-7, deposited in China Center for Type Culture Collection (CCTCC), with the deposit number CCTCC NO: M 2024523 and the deposit date of March 18, 2024.

2. The lactic acid bacteria according to claim 1, characterized in that Its gene sequence is shown in SEQ ID NO.

1.

3. Use of the lactic acid bacteria according to claim 1 or 2 in the preparation of probiotics.

4. A probiotic agent, characterized in that: Containing the lactic acid bacteria SCZH-7 according to claim 1, or a bacterial liquid containing lactic acid bacteria SCZH-7, or a fermentation liquid containing lactic acid bacteria SCZH-7, or a freeze-dried powder containing lactic acid bacteria SCZH-7.

5. A probiotic according to claim 4, characterized in that: The viable count of the lactic acid bacteria SCZH-7 in the probiotic is 10 8 -10 9 CFU / mL.

6. A probiotic according to claim 4 or 5, characterized in that: The method for preparing the bacterial liquid comprises the following steps: Take a single colony of SCZH-7 and inoculate it into MRS broth, culture it at 37°C for 23-25h to obtain bacterial liquid.

7. A probiotic according to claim 4 or 5, characterized in that: The method for preparing the fermentation broth comprises the following steps: A single colony of SCZH-7 was inoculated into MRS broth and cultured at 37°C for 23-25 ​​h to obtain an activated bacterial solution. The activated bacterial solution was centrifuged for 8-12 min to remove the bacteria, and then filtered through a microporous filter membrane to obtain a fermentation broth.

8. A probiotic according to claim 4 or 5, characterized in that: The preparation method of the freeze-dried powder comprises the following steps: Take a single colony of SCZH-7 and inoculate it into MRS broth, culture it at 37 °C for 23-25 ​​h to obtain an activated bacterial solution, add the activated bacterial solution into a freezing tube, add an equal volume of sterile skim milk, then plug the top of the freezing tube with an absorbent cotton ball, and freeze-dry it under vacuum to obtain a lyophilized powder.

9. Use of the lactic acid bacteria according to claim 1 and the probiotic according to claim 4 or 5 in the preparation of dairy products, cosmetics, fermented foods, and antimicrobial additives for inhibiting infection by Gram-positive and Gram-negative pathogens.

10. An antimicrobial additive for inhibiting infection by Gram-positive and Gram-negative pathogens, characterized in that: The antimicrobial additive contains the lactic acid bacteria according to claim 1 or the probiotic agent according to any one of claims 4-5.

Citation Information

Patent Citations

  • Lactic acid bacterium with wide-spectrum bacteriostatic activity and application thereof

    CN104611251A

  • Lactobacillus plantarum JM113 and application thereof

    CN105543126A

  • Lactobacillus plantarum and application thereof

    CN116179393A

Cited By

  • Phytobacterium plantarum WKLPP0041 with high BSH activity as well as mutagenesis screening method and application of phytobacterium plantarum WKLPP0041

    CN119913071A